Clinical trials in Arnhem – page 17

787 clinical trials in Arnhem, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Arnhem at a glance

787

clinical trials

Research sites1

Quick filters

787 trials in Arnhem

Open in trial search

Tuberculosis

Recruiting

Study on High-Dose Rifampicin Safety for Adults with Complex Tuberculosis Using Isoniazid, Pyrazinamide, and Ethambutol Combination

Registered drugNo placebo

Study on High-Dose Rifampicin Safety for Adults with Complex Tuberculosis Using Isoniazid, Pyrazinamide, and Ethambutol Combination

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Isoniazid
Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Contact Research Centre

Peripheral arterial occlusive disease+1

Recruiting

Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks

Registered drug

Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Colchicine
Sponsor:Hamilton Health Sciences Corporation

Contact Research Centre

Appendicitis+4

Recruiting

Study on Using Gentamicin and Clindamycin to Prevent Abscesses After Surgery for Complicated Appendicitis in Patients

Registered drugNo placebo

Study on Using Gentamicin and Clindamycin to Prevent Abscesses After Surgery for Complicated Appendicitis in Patients

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Clindamycin
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Paroxysmal nocturnal haemoglobinuria

Recruiting

Study on Optimizing Ravulizumab Dosing for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo

Study on Optimizing Ravulizumab Dosing for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ravulizumab
Sponsor:Radboud universitair medisch centrum Stichting

Contact Research Centre

Breast cancer

Recruiting

Study of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease

Registered drugNo placebo

Study of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Small cell lung cancer extensive stage

Recruiting

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Subarachnoid haemorrhage

Recruiting

Study on Deferoxamine for Patients with Aneurysmal Subarachnoid Hemorrhage

Registered drug

Study on Deferoxamine for Patients with Aneurysmal Subarachnoid Hemorrhage

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Deferoxamine Mesilate
Sponsor:Radboud universitair medisch centrum Stichting

Contact Research Centre

Malignant melanoma

Recruiting

Study on Stopping Nivolumab or Pembrolizumab in Advanced Melanoma Patients After Achieving a Response

Registered drugNo placebo

Study on Stopping Nivolumab or Pembrolizumab in Advanced Melanoma Patients After Achieving a Response

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of JNJ-90301900 with Chemoradiation and Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer

InvestigationalNo placebo

Study of JNJ-90301900 with Chemoradiation and Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Hafnium oxide
Sponsor:Johnson And Johnson Enterprise Innovation Inc.

Contact Research Centre

Breast cancer

Recruiting

Study on Low-Dose Gadolinium for Breast Cancer MRI in Patients Using Gadoteric Acid

Registered drugNo placebo

Study on Low-Dose Gadolinium for Breast Cancer MRI in Patients Using Gadoteric Acid

Registered drugNo placebo

The Netherlands

Participants:18–64 years
Substances:Gadoteric Acid
Sponsor:Radboud universitair medisch centrum Stichting

Contact Research Centre

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Upadacitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Still's disease+1

Recruiting

Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo

Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo

The Netherlands

Participants:0–17 years
Substances:Anakinra
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Arnhem

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on advanced gastric cancer, bladder cancer, and various forms of leukemia. Studies include evaluation of novel imaging techniques and combination therapies for better treatment outcomes.

Gastric Cancer Staging
Bladder Cancer Therapeutics
Acute Myeloid Leukemia Treatment

Multiple trials exploring targeted therapies and innovative diagnostic approaches for various cancer types.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management and prevention, including research on post-stroke care and cardiac arrest treatments.

Stroke Treatment Protocols
Cardiac Arrest Management
Cardiovascular Risk Reduction

Focus on improving patient outcomes through innovative therapeutic approaches and prevention strategies.

03 Metabolic Disorders

Clinical investigations targeting obesity and weight management, with emphasis on new therapeutic agents and their cardiovascular safety profiles.

Weight Management Therapies
Metabolic Disease Treatment
Safety Assessments

Evaluating novel approaches to treating metabolic disorders and their associated complications.

Back to the Netherlands All countries